Tuberculosis multidrogorresistente

Vista sencilla de ítem
dc.contributor.authorUrrego-Díaz, José Augusto
dc.contributor.orcidUrrego-Díaz, José Augusto[0000-0002-5234-2112]
dc.date.accessioned2021-05-06T14:04:59Z
dc.date.available2021-05-06T14:04:59Z
dc.date.issued2020-07-22
dc.description.abstractLa tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 mi-llones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamientospa
dc.description.abstractenglishTuberculosis (TB) is the worldwide leading infectious cause of death and, the emergence of drug-resistant tuberculosis can only worsen the scenario. Multidrug-Resistant Tuberculosis (TB-MDR) has proven resistant to both isoniazid and rifampin, the main antituberculous drugs. Out of 10 million people developing TB annually, 458 000 exhibit TB-MDR, having worse prognosis than those infected by sensitive strains. Recently, new drug-re-sistant TB treatment guidelines were issued both by the World Health Or-ganization and health authorities in Colombia. The present paper explores the main aspects of TB-MDR emphasizing s sanitary authorities also, new guidelines were published by Colombian minister of health and social pro-tection. In this paper, the main aspects of TB-MDR are explored, especially those related to its treatment.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.18270/rsb.v10i1.2834
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn2322-9462
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5832
dc.language.isospa
dc.publisher.journalRevista Salud Bosquespa
dc.relation.ispartofseriesRev. salud. bosque /ISSN 2322-946 / Volumen 10 /ene. - jun . de 2020 / Número 1/ Págs. 80-8spa
dc.relation.referencesMurray PR, Rosenthal KS, Pfaller MA. Mycobacterium. En: Microbiología médica. 6ta ed. Barcelona: Elsevier España; 2009.spa
dc.relation.referencesKumar V, Abbas AK, Fausto N, Aster JC. Micobacterias. En: Robbins y Cotran: Patología estructural y funcional. 8va ed. Barcelona: Elsevier España; 2010.spa
dc.relation.referencesWorld Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019.spa
dc.relation.referencesRaviglione MC. Tuberculosis. En: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editores. Ha-rrison: Principios de medicina interna. 18va ed. New York: McGraw-Hill; 2012spa
dc.relation.referencesColombia. Instituto Nacional de Salud (INS). Informe de evento: Tuberculosis, Colombia, 2017. Bogotá, D.C.: INS; 2018.spa
dc.relation.referencesHouben RM, Dodd PJ. The Global Burden of Latent Tuber-culosis Infection: A Re-estimation Using Mathematical Mo-delling. PLoS Med. 2016;13(10):e1002152. DOI: 10.1371/journal.pmed.1002152spa
dc.relation.referencesOrganización Panamericana de la Salud (OPS). Tuberculosis en las Américas 2018. Washington, D.C.: OPS; 2018.spa
dc.relation.referencesColombia. Instituto Nacional de Salud (INS). Boletín Epi-demiológico Semanal. Semana epidemiológica 38. Bogotá D.C.: INS; 2018spa
dc.relation.referencesGandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tu-berculosis. Lancet. 2010;375(9728):1830-43. DOI: 10.1016/S0140 - 6736(10)60410 -2spa
dc.relation.referencesDaley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis. Semin Respir Crit Care Med. 2018;39(3):310 -24. DOI: 10.1055/s- 0038 -1661383spa
dc.relation.referencesColombia. Ministerio de Salud y Protección Social (MinSalud). Circular externa 55 de 2016 (diciembre 20): Actualización DE los lineamientos para el manejo progra-mático de tuberculosis en niños, casos farmacoresistentes y aspectos de la programación de sintomáticos respirato-rios. Bogota D.C.: MinSalud; 2016spa
dc.relation.referencesCenters for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know. 6ta ed. CDC; 2013spa
dc.relation.referencesColombia. Ministerio de Salud y Protección Social, Institu-to Nacional de Salud. Lineamientos para el manejo progra-mático de pacientes con tuberculosis farmacorresistente. Bogotá D.C.: MinSalud; 2013spa
dc.relation.referencesGarzón MC, Angée DY, Llerena C, Orjuela DL, Victoria JE. Vigilancia de la resistencia del Mycobacterium tuberculo-sis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica. 2008:28(3):319-26. DOI: 10.7705/biomedica.v28i3.71spa
dc.relation.referencesMak A, Thomas A, Del Granado M, Zaleskis R, Mouza-farova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized re-gimens. Am J Respir Crit Care Med. 2008;178(3):306-12. DOI: 10.1164/rccm.200802-240OCspa
dc.relation.referencesLew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123-34. DOI: 10.7326/0003-4819-149-2-200807150-0000spa
dc.relation.referencesWorld Health Organization (WHO). Global tuberculosis report 2017. Geneva: WHO; 2017spa
dc.relation.referencesColombia. Instituto Nacional de Salud (INS). Informe de actividades realizadas por la Red Nacional de Laborato-rios para la vigilancia de la resistencia de Mycobacterium tuberculosis a los fármacos Antituberculosos, Colombia 2013. Bogotá D.C.: INS; 2014.spa
dc.relation.referencesColombia. Instituto Nacional de Salud (INS). Protocolo de vigilancia en salud pública: Tuberculosis farmacoresisten-te. Bogotá, D.C.: INS; 2017spa
dc.relation.referencesWorld Health Organization (WHO). Treatment of tubercu-losis: guidelines for national programmes. Geneva: WHO; 2003. WHOspa
dc.relation.referencesWorld Health Organization (WHO). Global tuberculosis report 2016. Geneva: WHO; 2016.spa
dc.relation.referencesCenters for Disease Control and Prevention (CDC). Labora-tory User Guide for U.S. Public Health Laboratories: Mole-cular Detection of Drug Resistance (MDDR) in Mycobac-terium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. Atlanta: CDC; 2012 [citado 2019 sep 14]. Disponible en: https://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdfspa
dc.relation.referencesTelenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax. 1998;53(9):793-7. DOI: 10.1136/thx.53.9.793.spa
dc.relation.referencesFontalvo-Rivera D, Gómez-Camargo D. Genes del Myco-bacterium tuberculosis involucrados en la patogenicidad y resistencia a antibióticos durante la tuberculosis pulmonar y extrapulmonar. Medicas UIS. 2015;28(1):39-51.spa
dc.relation.referencesSacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol. 1996;147(1-2):36-43. DOI: 10.1016/0923-2508(96)80201-4spa
dc.relation.referencesZhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacte-rium tuberculosis. Nature. 1992;358(6387):591-3. DOI: 10.1038/358591a0spa
dc.relation.referencesHeym B, Alzari PM, Honoré N, Cole ST. Missense muta-tions in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995;15(2):235-45. DOI: 10.1111/j.1365-2958.1995.tb02238.xspa
dc.relation.referencesCockerill FR, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995;171(1):240 -5. DOI: 10.1093/ infdis /171.1.240spa
dc.relation.referencesBrennan PJ, Nikaido H. The envelope of mycobacteria. An-nu Rev Biochem. 1995;64:29-63. DOI: 10.1146/annurev.bi.64.070195.000333spa
dc.relation.referencesRozwarski DA, Grant GA, Barton DH, Jacobs WR, Sa-cchettini JC. Modification of the NADH of the isonia-zid target (InhA) from Mycobacterium tuberculosis. Science. 1998;279(5347):98-102. DOI: 10.1126/scien-ce.279.5347.98spa
dc.relation.referencesBloom BR. Tuberculosis: Pathogenesis, Protection, and Control. Washington DC: ASM Press; 1994spa
dc.relation.referencesMiller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Che-mother. 1994;38(4):805-11. DOI: 10.1128/aac.38.4.805spa
dc.relation.referencesTelenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f.spa
dc.relation.referencesCole ST. Rifamycin resistance in mycobacteria. Res Microbiol. 1996;147(1-2):48-52. DOI: 10.1016/0923-2508(96)80203-8spa
dc.relation.referencesWorld Health Organization (WHO). Consolidated guide-lines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019.spa
dc.relation.referencesWorld Health Organization (WHO). WHO Treatment Gui-delines for Drug-Resistant Tuberculosis: 2016 Update. Ge-neva: WHO; 2016.spa
dc.relation.referencesColombia. Ministerio de Salud y Protección Social. Linea-mientos técnicos y operativos del programa nacional de tuberculosis [documento en consulta interna]. Bogotá: MinSalud; 2019.38spa
dc.relation.referencesWorld Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011.spa
dc.relation.referencesWorld Health Organization (WHO). The Use of bedaqui-line in the Treatment of MultidrugResistant Tuberculosis: Interim Policy Guidance. Geneva: WHO; 2013spa
dc.relation.referencesWorld Health Organization (WHO). The Use of delamanid in the Treatment of MultidrugResistant Tuberculosis: Inte-rim Policy Guidance. Geneva: WHO; 2014spa
dc.relation.referencesWorld Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016spa
dc.relation.referencesWorld Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016spa
dc.relation.referencesWorld Health Organization (WHO). Guidelines for the treatment of drug-susceptible tuberculosis and patient ca-re: 2017 update. Geneva: WHO; 2017spa
dc.relation.referencesWorld Health Organization (WHO). WHO treatment gui-delines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tubercu-losis. Geneva: WHO; 2018spa
dc.relation.referencesWorld Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis: 2018 update. Geneva: WHO; 2018.spa
dc.relation.referencesNahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Socie-ty/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. DOI: 10.1093/cid/ciw376.spa
dc.relation.referencesCurry International Tuberculosis Center. Drug-Resistant Tu-berculosis: A Survival Guide for Clinicians. 3ra ed. Wash-ington D.C.; CITC; 2016spa
dc.relation.referencesWorld Health Organization (WHO). Rapid communica-tion: key changes to treatment of multidrug- and rifampi-cin-resistant tuberculosis (TB-MDR/RR). Geneva: WHO; 2019 [citado 2019 sep 20]. Disponible en: https://www.who.int/tb/publications/2019/WHO_RapidCommunica-tionMDRTB2019.pdf?ua=1.spa
dc.relation.referencesNunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201-13. DOI: 10.1056 / NEJM oa1811867.spa
dc.relation.referencesDeltyba (delamanid). Amsterdam: European Medicines Agency; 2018 [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/deltybaspa
dc.relation.referencesSirturo (bedaquiline). Amsterdam: European Medicines Agency; 2014. [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/sirturospa
dc.relation.referencesWorld Health Organization (WHO). WHO best-practice statement on the off-label use of bedaquiline and delama-nid for the treatment of multidrug-resistant tuberculosis. Geneva: WHO; 2017 [citado 2019 sep 27]. Disponible en: https://apps.who.int/iris/bitstream/10665/258941/1/WHO-HTM-TB-2017.20-eng.pdfspa
dc.relation.referencesVan Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive stan-dardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92. DOI: 10.1164/rccm.201001-0077OCspa
dc.relation.referencesKuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for TB-MDR patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517-24. DOI: 10.5588/ijtld.14.0535.spa
dc.relation.referencesPiubello A, Harouna SH, Souleymane MB, Boukary I, Mo-rou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188-94. DOI: 10.5588/ijtld.13.0075.spa
dc.relation.referencesAhmad-Khan F, Salim MAH, du Cros P, Casas EC, Kha-mraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate da-ta meta-analyses. Eur Respir J. 2017;50(1):1700061. DOI: 10.1183/13993003.00061-2017.spa
dc.relation.referencesWorld Health Organization (WHO). Position Statement on the Continued Use of the Shorter TB-MDR Regimen fo-llowing an Expedited Review of the STREAM Stage 1 Preli-minary Results. Geneva: WHO; 2018spa
dc.relation.referencesMoodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Res-pir Rev. 2016;25(139):29-35. : 10.1183/16000617.0080-2015spa
dc.relation.referencesCaminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006spa
dc.relation.referencesCaminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006spa
dc.relation.referencesAhuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.spa
dc.relation.referencesAhuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.spa
dc.relation.referencesAhmad N, Ahuja SD, Akkerman OW, Alffenaar JC, An-derson LF, Baghaei P, et al. Treatment correlates of suc-cessful outcomes in pulmonary multidrug-resistant tu-berculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-34. DOI: 10.1016/S0140-6736(18)316 4 4 -1spa
dc.relation.referencesHarausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e10 02591. DOI: 10.1371/journal.pmed.10 02591.spa
dc.relation.referencesvon Groote-Bidlingmaier F, Patientia R, Sanchez E, Ba-lanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-con-trolled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249-59. DOI: 10.1016/S2213-2600(18)30426-0.spa
dc.relation.referencesZhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug re-sistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 ;68(9):1522-1529. DOI: 10.1093/cid/ciy727spa
dc.relation.referencesBorisov SE, Dheda K, Enwerem M, Romero-Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safe-ty of bedaquiline-containing regimens in the treatment of MDR- and XTB-DR: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017.spa
dc.relation.referencesSchnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retros-pective cohort study. Lancet Respir Med. 2018;6(9):699-706. DOI: 10.1016/S2213-2600(18)30235-2.spa
dc.relation.referencesDiacon AH, Pym A, Grobusch MP, de los Rios JM, Go-tuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32. DOI: 10.1056 / NEJM oa1313865spa
dc.relation.referencesDiacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397- 405. DOI: 10.1056/NEJMoa0808427spa
dc.relation.referencesDiacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Che-mother. 2012;56(6):3271-6. DOI: 10.1128/AAC.06126-11spa
dc.relation.referencesSingh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):CD012836. DOI: 10.1002/14651858.CD012836.pub2.spa
dc.relation.referencesKoh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for mul-tidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858-64. DOI: 10.1164/rccm.201303-0604OC.spa
dc.relation.urihttps://revistasaludbosque.unbosque.edu.co/index.php/RSB/article/view/2834
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectTuberculosisspa
dc.subjectInfecciónspa
dc.subjectFarmacorresistencia Microbianaspa
dc.subjectQuimioterapiaspa
dc.subjectAgentes Antibuberculososspa
dc.subject.keywordsTuberculosisspa
dc.subject.keywordsInfectionspa
dc.subject.keywordsMultidrug-Resistantspa
dc.subject.keywordsTreatmentspa
dc.subject.keywordsAntitubercular Agentsspa
dc.titleTuberculosis multidrogorresistentespa
dc.title.translatedMultidrug-resistant tuberculosisspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.coarversionhttps://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PORTADA1.png
Tamaño:
3.18 MB
Formato:
Portable Network Graphics
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Revista Salud Bosque